N/A N=7 "GameDay Ready": Evaluating a Behavioral Weight Management Program for Black Men Living in the Rural South
Obesity · Physical Inactivity · Diet, Healthy
Primary: Study Interest — 91 Number of people
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=122 Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in IDS-SR-10 Engagement — -8.11 score on a scale — p=<0.0001
N/A N=85 Endothelial Function After Cardiac Surgery
Endothelial Dysfunction
Primary: Reactive Hyperemia Index (RHI) — 1.88; 1.61 ratio — p=0.158
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 4 N=22 Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
Skin Diseases, Bacterial
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 16; 4; 0; 0 Participants
N/A N=129 Blinded Dry Mouth Spray Crossover Study
Xerostomia · Head and Neck Cancer · Xerostomia Following Radiotherapy
Primary: Oral Dryness — 45.5; 46.6; 52.76; 54.1 units on a scale — p=<0.501
N/A N=182 A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research
Dementia · Cognitive Dysfunction · Alzheimer Disease
Primary: Number of Participants Enrolled in Each Recruitment Arm — 182 Participants
Phase 2 N=57 Study in Subjects With Small Primary Choroidal Melanoma
Uveal Melanoma · Ocular Melanoma · Choroidal Melanoma
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] of Light-activated AU-011 — 3; 3; 3; 3 Participants
N/A N=977 Aging and Cognitive Health Evaluation in Elders (ACHIEVE)
Aging · Cognitive Decline
Primary: Change in Global Cognitive Function — -0.202; -0.200 score on a scale — p=0.96
Phase 1 N=97 A Study of Lasmiditan in Healthy Volunteers
Healthy
Primary: Part 1 Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran to Assess P-glycoprotein (P-gp) Activity. — 138; 168 nanograms/milliliter (ng/mL)
Phase 2 N=572 A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
Seasonal Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 37; 63; 59; 60 Participants
Phase 2 N=37 Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Difference in Square-Root Transformed GA Area Expansion Rates in the Study Eye Between the Treatment Phase and Run-in Phase Based on Fundus Autofluorescence (FAF)…
Phase 1 N=18 Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Leukemia Lymphoblastic, Acute · Acute Myeloid Leukemia · Neoplasm Recurrent
Primary: Maximum Feasible Dose of Clofarabine — 52 mg/m^2
Phase 4 N=13 The Effect of Brimonidine
Intraocular Pressure
Primary: Intraocular Pressure — 15.4; 16.3; 16.5; 16.7 millimeters of mercury (mmHg)
N/A N=24 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position
Ureteral Obstruction
Primary: Incidence of Bladder Irritation Symptoms (e.g. Frequency, Urgency, Nocturia, Urine Leakage...) Associated With the RELIEF Stent. — 51.95 Units on a scale